



Rabbit anti-BCL2

Cat. No.: BRB055 (16 ml Ready-to-use)

Instructions for use

Intended Use

This antibody is designed for the specific localisation of BCL2 protein in formalin-fixed, paraffin-embedded tissue sections

Anti-BCL2 antibody is intended for in vitro diagnostic use.

Specifications

Specificity: BCL2
Clone: E17
Isotype: Rabbit IqG

Species reactivity: Human +, others not tested

Summary and explanation

This antibody against BCL2 detects neoplastic follicles in follicular lymphomas but is consistently negative in reactive germinal centres. Consequently staining of BCL2 in lymph node biopsies is a useful test in differentiation of reactive and neoplastic follicular proliferation.

This antibody may also be used in distinguishing between those follicular lymphomas that express BCL2 protein and the small number of cases in which the neoplastic cells are BCL2 negative.

Several publications show a higher sensitivity of the monoclonal rabbit antibody E17 for follicular lymphomas in comparison to established mouse monoclonal BCL2 antibodies (Masir *et al.* 2009, 2010, Adam *et al.* 2013). Additionally, certain investigations have shown that BCL2 has shown promise as a prognostic marker in case of breast carcinomas and non-small cell lung carcinomas.

Reagent provided

Monoclonal rabbit antibody in buffer with carrier protein and preservative for stabilisation in the following format: **Ready-to-use:** 16 ml (Cat. No. BRB055)

Dilution of primary antibody

None

Storage and handling

The antibody should be stored at 2-8°C without further dilution.

If necessary, dilutions of the antibody should be done with a suitable antibody dilution buffer (e.g. ZUC025 from Zytomed Systems). The diluted antibody should be stored at 2-8°C after use. Stability of this working solution depends on various parameters and has to be confirmed by appropriate controls.

The antibody provided is stable until the expiry date indicated on the label, if stored at 2-8°C. Do not use product after the expiry date. Positive and negative controls should be run simultaneously with all specimens. If unexpected staining is observed which cannot be explained by variations in laboratory procedures and a problem with the antibody is suspected, contact Zytomed Systems' technical support or your local distributor.

Precautions

Use through qualified personnel only. Wear protective clothing to avoid contact of reagents and specimens with eye, skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with large amounts of water.

Microbial contamination of the reagent must be avoided, since otherwise non-specific staining may occur. ProClin300 and sodium azide (NaN₃) are used for stabilisation. Reaction of sodium azide with lead or copper in drainage pipes can result in the formation of highly explosive metallic azides. Discard the antibody solution in a large volume of running water to avoid formation of deposits. A material safety data sheet (MSDS) for the pure substances is available upon request.

Date of approval: 2023-03-08 Revision: V01 Page 1 of 2

Staining procedure

Refer to the following table for conditions specifically recommended for this antibody. Also refer to detection system data sheets for guidance on specific staining protocols or other requirements.

<u>Parameters</u> <u>Zytomed Systems recommendations</u>

*Pre-treatment: Heat Induced Epitope Retrieval (for example in Citrate buffer pH 6.0)

*Control tissue Tonsils, lymph nodes

*Working dilution None
*Incubation time 60 minutes

Quality control

The recommended positive control tissue for this antibody are tonsils and lymph nodes. Please refer to the instructions of the detection system for guidance on general quality control procedures.

Troubleshooting

If you observe unusual staining or other deviations from the expected results please read these instructions carefully, refer to the instructions of the detection system for relevant information or contact your local distributor.

Expected results

The antibody stains positive in the cytoplasm of BCL2 expressing cells in formalin-fixed, paraffin-embedded tissue. Further details about the expression pattern of BCL2 can be found in the chapter 'Summary and Description'. The interpretation of the results is solely the responsibility of the user. Any experimental result should be confirmed by a medically established diagnostic procedure.

Limitations of the Procedure

Immunohistochemistry is a complex technique involving both histological and immunological detection methods. Tissue processing and handling prior to immunostaining, for example variations in fixation and embedding or the inherent nature of the tissue can cause inconsistent results (Nadji and Morales, 1983). Endogenous peroxidase, alkaline phosphatase or biotin may cause non-specific staining depending on the detection system used. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive results with HRP (horse radish peroxidase) detection systems (Omata *et al*, 1980). Inadequate counterstaining and mounting can influence the interpretation of the results.

Zytomed Systems warrants that the product will meet all requirements described from its shipping date until the expiry date is reached, if the product is stored and utilised as recommended. No additional guarantees can be given. Under no circumstances shall Zytomed System be liable for any damages arising out of the use of the reagent provided.

Performance characteristics

Zytomed Systems has conducted studies to evaluate the performance of the antibody utilising a standard detection system. The product has been found to be sensitive and specific to the antigen of interest with minimal or no cross-reactivity.

Bibliography

Nadji M and Morales AR. Ann NY Acad Sci 420:134-139, 1983 Tsujimoto Y *et al.* Proc Natl Acad Sci USA 83:5214-5218, 1986 Hockenbery D *et al.* Nature 348:334-336, 1990 Moul JW *et al.* Eur Urol 35:399-407, 1999 Martin B *et al.* Brit J Cancer 89:55-64, 2003 Masir N *et al.* Pathology 42:212-216, 2010

Cleary ML et al. Cell 47:19-28, 1986 Omata M et al. Am J Clin Pathol 73:626-632, 1989 Pezzella F et al. Am J Pathol 137:225-232, 1990 Ciocca DR, Elledge R Endocrinol 13:1-10, 2000 Masir N et al. Br J Haematol 144:716-725, 2009 Adam P et al. Hum Pathol 44:1817-1826, 2013



www.zytomed-systems.de



Zytomed Systems GmbH • Anhaltinerstraße 16 • 14163 Berlin, Germany • Tel: (+49) 30-804 984 990

Explanations of the symbols on the product label

Symbols are used in accordance with ISO 15223-1. Further symbols on the product label might be:



GSH07: Warning / Attention

For Research Use Only

Date of approval: 2023-03-08 Revision: V01 Page 2 of 2